Free Newsletter
Suitors bid as much as $7.8B for Actavis
File under 'it had to happen': Iceland's Actavis Group is asking for takeover bids. The generics maker could bring as much as $7.8 billion, MarketWatch reports, citing Bloomberg. Among the interested parties are--reportedly, anyway--Sanofi-Aventis, which has been putting together financing for potential deals; Teva Pharmaceutical Industries; and Watson Pharmaceuticals.
As you know, Actavis ran into big trouble last year when its private equity owner Novator, controlled by billionaire entrepreneur Thor Bjorggolfsson, ran afoul of the big Icelandic banking crisis. Bjorggolfsson lost a bundle in the financial collapse, leaving his concerns in need of cash. So Actavis hired Merrill Lynch to explore its options. Stay tuned.
- see the MarketWatch story
Related Articles:
Iceland's Actavis goes up for bid
Actavis downplays talk of sellout
From Iceland's woes, an $8B Actavis deal?
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: